in individuals from the
population sample. The risk of developing the pathology is increased 2 times
Kazantseva, A.V.,
Davydova, Yu. D.,
Enikeeva, R.F.,
Takhirova, Z.R.,
Mustafin, R.N.,
Lobaskova, M.M.,
Malykh, S.B.,
Khusnutdinova, E.K. (2023) .e., intelligence, educational level, executive functions, etc.) have been conducted in European
populations. A
of 1:3000 in human
population. About 50% of NF1 cases are sporadic due to newly emerging germline
Kazantseva, A.V.,
Davydova, Yu. D.,
Enikeeva, R.F.,
Yakovleva, D.V.,
Mustafin, R.N.,
Lobaskova, M.M.,
Malykh, S.B.,
Khusnutdinova, E.K. (2023) regression was carried out in the testing
sample (N = 500) from VUR with PGS calculated on a basis of effect
. The average incidence of NF1 in the world is 1:3000 of the
population. The characteristic signs of the disease
Nurgalieva, A.Kh.,
Bashkatov, S.A.,
Volkova, E.V.,
Petrova, S.G.,
Takhirova, Z.R.,
Mustafin, R.N.,
Fedorova, Y.Y.,
Prokofyeva, D.S.,
Khusnutdinova, E.K. (2023) students. DNA
samples recovered from peripheral blood lymphocytes of 197 adolescents (89 boys, 108 girls
disease affecting more than 10 % of the world's
population. Exporing immunological mechanisms
Mustafin, R.N.,
Bermisheva, M.A.,
Karunas, A.S.,
Akhmetshin, A.A.,
Monakhova, A.S.,
Khusnutdinova, E.K. (2025) of Bashkortostan, sequencing the NF1 gene in their DNA
samples as well as whole genome sequencing using the WGS
KAZANTSEVA, A.V.,
DAVYDOVA, YU.D.,
ENIKEEVA, R.F.,
LOBASKOVA, M.M.,
MUSTAFIN, R.N.,
MALYKH, S.B.,
TAKHIROVA, Z.R.,
KHUSNUTDINOVA, E.K. (2020) of genetic variants in a moderately large
sample, was used. Conclusions: Our preliminary findings indicate